Jaskirat Sethi

Assistant Professor

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

Internal Medicine, College of Medicine

4 h-index 11 pubs 60 cited

Research Areas

Links

Lab Website UAMS TRI Profile

OverviewAI-generated summary

Jaskirat Sethi is an Assistant Professor in Internal Medicine at the University of Arkansas for Medical Sciences. His research focuses on multiple myeloma, a hematologic malignancy. Dr. Sethi has investigated clinical outcomes for patients with relapsed refractory multiple myeloma undergoing CAR T-cell therapy directed at BCMA, as well as the feasibility and risk factors for outpatient stem cell transplantation in this patient population. His work also examines corneal toxicity associated with specific treatments like belantamab mafodotin and the characteristics and prognostic factors for patients with multiple myeloma admitted to the intensive care unit. He has also explored the stem cell origin of cancer and strategies for chemoprevention and maintenance therapy. Dr. Sethi collaborates with several researchers at the University of Arkansas for Medical Sciences, including Nishanth Thalambedu, Munawwar Hussain, Sravani Gundarlapalli, and Clyde Bailey.

Metrics

h-index: 4
Publications: 11
Citations: 60

Selected Publications

Revaccination status after bone marrow transplant and chimeric antigen receptor T-cell therapy. (2025)

DOI OpenAlex
Stem Cell Origin of Cancer: Biological Principles and Clinical Strategies for Chemoprevention and Maintenance Therapy in Cancer Care (2025)

1 citation DOI OpenAlex
Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature (2023)

2 citations DOI OpenAlex
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy (2022)

21 citations DOI OpenAlex
Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy (2022)

7 citations DOI OpenAlex
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022)

DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

DOI OpenAlex
MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

DOI OpenAlex
Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience (2022)

14 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

13 citations DOI OpenAlex